Roth MKM lowered the firm’s price target on Atlas Lithium to $39 from $47 and keeps a Buy rating on the shares. The price target decrease reflects lower spodumene price assumptions for 2025 and beyond, but Roth MKM believes investor interest could shift towards spodumene projects in the current price environment, the analyst says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ATLX: